Novamab, founded in October 2017 and based in the Shanghai International Medical Park, is a pioneering biopharmaceutical company specializing in sdAb drug research and industrialization. The company has established a comprehensive R&D, CMC, and pilot production platform, making it the only firm in China with full-process development capabilities for sdAb drugs.

Novamab has constructed a 500L Pichia pastoris sdAb GMP pilot production workshop, addressing a significant industry gap and enhancing competitiveness. By January 2025, the company had filed over 80 domestic and international invention patents, with 31 already granted. Its R&D pipeline spans respiratory, immunotherapy, ophthalmology, and oncology fields, securing four clinical approvals. Notably, LQ036 and LQ043H, the world's first inhaled sdAb drugs for respiratory diseases, have shown promising results. LQ036 has completed Phase I trials in China and Australia and is now in Phase II in China, demonstrating excellent safety and biomarker efficacy. LQ043H has completed a clinical Ia study in China, showing strong safety and tolerance. Additionally, the company is leveraging sdAb advantages to develop dual and multi-antibody platforms, with rapid progress in inflammatory bowel disease (IBD) and other autoimmune disease projects.